Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALT-803 in HIV Infected People on Optimized ART
NCT02191098Phase 1Completed
- Sponsor
- University of Minnesota
- Start
- Jun 2015
- Primary completion
- Sep 2019
- Modality
- Cytokines & Interferons, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of nogapendekin alfa inbakicept in human immunodeficiency virus infection (HIV), sponsored by University of Minnesota. Primary endpoint: Safety and Tolerability at 4 weeks. Started Jun 2015; status: completed.
02
Drugs
nogapendekin alfa inbakicept
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT02191098.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02191098.